| Phase 13 trials |
|
Phase 1
|
NCT06350006 |
May 2024 → Dec 2027 expected |
— |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04928625 |
Aug 2021 → Jun 2023 |
pancreatic neoplasm |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04877717 |
Jul 2021 → Dec 2025 overdue |
cancer |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT05277168 |
May 2022 → May 2026 overdue |
cancer |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 27 trials |
|
Phase 2
|
NCT07700719 |
Jul 2026 → Nov 2027 expected |
colorectal cancer |
Peking University Cancer Hospital & Institute |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07520357 |
Apr 2026 → Feb 2028 expected |
neuroendocrine carcinoma |
Beijing GoBroad Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07450976 |
Mar 2026 → Dec 2030 expected |
biliary tract cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07102901 |
Sep 2025 → Dec 2027 expected |
gastric cancer, gastroesophageal junction adenocarcinoma |
Jiangsu HengRui Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07110571 |
Aug 2025 → Aug 2026 overdue |
gastric cancer, gastroesophageal cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06881017 |
May 2025 → Aug 2029 expected |
gastric cancer, gastroesophageal junction adenocarcinoma |
China Medical University, China |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06547736 |
Oct 2024 → Mar 2027 expected |
malignant pancreatic neoplasm |
Fudan University |
Recruiting
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT06649292 |
Nov 2024 → Sep 2027 expected |
gastroesophageal adenocarcinoma |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|